Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01191775 · ClinicalTrials.gov registry record · Phase 1
A Study of PNT2258 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Sierra Oncology LLC - a GSK company.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01191775: Completed Phase 1 study, sponsored by Sierra Oncology LLC - a GSK company.
NCT01191775 is a Phase 1 study that has completed, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01191775, a Phase 1 study, has completed, sponsored by Sierra Oncology LLC - a GSK company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. The purpose of this research study is to evaluate the safety of the investigational drug PNT2258 in patients with advance tumors and see how it acts in the body.
Primary Outcome
Safety and tolerability of PNT2258 and the determination of dose-limiting toxicities (DLTs) and the recommended Phase 2 dose
Interventions
- DRUG PNT2258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
What the finished NCT01191775 record still lists
NCT01191775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 1 intervention - of which PNT2258 is the first listed.
NCT01191775 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01191775 about?
NCT01191775 is a clinical study titled "A Study of PNT2258 in Patients With Advanced Solid Tumors". This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. The purpose of this research study is to evaluate the safety of the investigational drug PNT2258 in patients with advance tumors and see how it acts in the body.
What is the current status of trial NCT01191775?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2010-08. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01191775?
The interventions under investigation include: PNT2258 (DRUG).
Who is sponsoring clinical trial NCT01191775?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01191775's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia